PKTX - ProtoKinetix, Incorporated

Other OTC - Other OTC Delayed Price. Currency in USD
0.1824
+0.0024 (+1.33%)
At close: 3:49PM EST
Stock chart is not supported by your current browser
Previous Close0.1800
Open0.1750
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1700 - 0.1850
52 Week Range0.0500 - 0.3200
Volume83,587
Avg. Volume74,662
Market Cap49.749M
Beta (5Y Monthly)1.98
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • Business Wire

    ProtoKinetix Files for Patent Protection for the Use of AAGP® in Transplant Medicine

    ProtoKinetix files for patent protection for the use of AAGP® in transplant medicine

  • Business Wire

    ProtoKinetix Takes Delivery of GMP AAGP® PKX-001 Dedicated for Phase 1 Trial

    ProtoKinetix Takes Delivery of GMP AAGP® PKX-001 Dedicated for Phase 1 Trial

  • Business Wire

    ProtoKinetix AAGP® Dry Eye Therapy Testing Results

    ProtoKinetix AAGP® Dry Eye Therapy Testing Results

  • Business Wire

    ProtoKinetix Achieves Primary Objective Safety at Midpoint of Clinical Trial

    ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB:PKTX) today announced reaching the midpoint of a Phase-1 first-in-human clinical trial of AAGP® PKX-001 treated islet cells used in conjunction with the Edmonton Protocol for the treatment of Type-1 diabetes. All primary safety objectives have been achieved at the midpoint in all study participants. As such, the protocol will now be amended to increase the number of participants in the trial with additional secondary objectives added, including dose escalation to establish optimization criteria for efficacy testing.

  • Business Wire

    ProtoKinetix First in Series of Town Hall Shareholder Meetings

    ProtoKinetix, Incorporated today announces that it will hold the first in a series of Town Hall Meetings. This meeting is being held to update shareholders on the current status of the company’s ongoing research projects.

  • Business Wire

    Agreement Secured by ProtoKinetix to Start Heart Research Product Validation Studies

    ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB:PKTX) is announcing that the Company has secured a partnership agreement with IMPART investigator team Canada at Dalhousie University and has now commenced studies to reveal the benefits of PKX-001 (AAGP®) in cardiac metabolism. As the director of the IMPART cardiometabolic research program, Dr. Pulinilkunnil leverages extensive training in molecular and metabolic sciences from his training at the University of British Columbia, the University of Alberta Heart Institute and Harvard Medical School.

  • Business Wire

    ProtoKinetix Discusses Investor Awareness Campaign and Recent Market Activity

    ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX) has been requested by OTC Markets Group to comment on certain recent promotional activity encouraging investors to purchase the Company’s common shares. The Company first became aware of certain promotional third-party newsletter activities from OTC Markets Group on May 2, 2019. Effective May 1, 2019 the Company engaged two investor relations groups to launch a marketing campaign, Burdell Partners LLC and Murdock Capital Partners Corp. The campaign was designed to bring the awareness of the investment community to the Company’s progress and continued successes in multiple health related studies and clinical trials.

  • Business Wire

    ProtoKinetix AAGP® in Phase 3 Retinal Replacement Program

    ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB:PKTX) updates its stockholders regarding phase 3 of testing using AAGP® in retinal cell replacement therapy at the University of British Columbia. The study is now using 2-animal models and a significantly larger number of animals in both control and AAGP® treated groups for a longer time frame. This study is being conducted to test whether AAGP® treated cells continue to develop into retinal cells.